Skip to Content

Blinatumomab use while Breastfeeding

Drugs containing Blinatumomab: Blincyto

Medically reviewed by Drugs.com. Last updated on Jan 15, 2021.

Blinatumomab Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the clinical use of blinatumomab during breastfeeding. Because blinatumomab is a large protein molecule with a molecular weight of about 54,000 Da, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, blinatumomab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. The manufacturer recommends that breastfeeding be discontinued during blinatumomab therapy and for at least 48 hours after treatment.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Blinatumomab

CAS Registry Number

853426-35-4

Drug Class

Breast Feeding

Lactation

Antibodies, Monoclonal

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.